Europe
Novel target class with dual action in inflammatory disorders
Galapagos NV expands its clinical study program with GLPG1690 in systemic sclerosis, following the recent start of the ISABELA Phase 3 program with ‘1690 in IPF.
In a special report published by Reuters last month, Michele Gershberg describes the painstaking medical journey of her 4-year-old son. “It was March 2017. Over the previous year, the signs had mounted that something was wrong.”
Tarrytown, NY-based Regeneron Pharmaceuticals and Paris-based Sanofi restructured a 2015 agreement to develop immuno-oncology (I/O) treatments. That deal was scheduled to wrap in 2020, but the revision adds two clinical-stage bispecific antibodies to the collaboration.
The white-hot biotech hub of Kendall Square just got a little bit more crowded. Ireland-based Allergan plc announced this morning that the company will establish an R&D facility in the Cambridge, Mass. neighborhood.
Biotech entrepreneur Vivek Ramaswamy has launched another subsidiary for Roivant Sciences. Ramaswamy will provide an update on the new company, as well as other members of the Roivant family during a Monday presentation at JPM19.
Fibrocor Therapeutics L.P. and Galapagos NV announced a global partnership focused on a novel target for idiopathic pulmonary fibrosis (IPF) and other indications.
A mechanism expected to overcome checkpoint blockade in T cells
Potential for new immune-oncology therapy using an antibody drug conjugate that targets regulatory T cells
PRESS RELEASES